Trials / Completed
CompletedNCT00969319
Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 105 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Male
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aim of this international prospective post-marketing surveillance study is to obtain data on treatment procedures, long-term safety and efficacy and patient acceptance of KOGENATE Bayer/FS in treatment of patients with haemophilia A under daily-life treatment conditions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Recombinant Factor VIII (Kogenate FS, BAY14-2222) | Patients under daily life treatment receiving Kogenate according to local drug information. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2013-02-01
- Completion
- 2014-02-01
- First posted
- 2009-09-01
- Last updated
- 2015-01-19
Locations
2 sites across 2 countries: Mexico, Venezuela
Source: ClinicalTrials.gov record NCT00969319. Inclusion in this directory is not an endorsement.